查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1418372

被忽視的熱帶疾病診斷市場報告：2030 年趨勢、預測與競爭分析

Neglected Tropical Disease Diagnosis Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 - page report | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

被忽視的熱帶疾病診斷（NTD）的趨勢和預測

預計 2024 年至 2030 年，全球被忽視的熱帶疾病診斷市場將以 4.9% 的複合年成長率成長。這個市場的主要驅動力是被忽視的熱帶疾病數量的增加、對快速診斷測試的需求不斷增加以及對被忽視的熱帶疾病的認知不斷提高。全球被忽視的熱帶疾病診斷市場的未來對於醫院和診所、家庭醫療保健和臨床檢測市場來說是充滿希望的。

被忽視的熱帶疾病診斷市場洞察

Lucintel 預測，由於已開發國家擴大採用就地檢驗來檢測登革熱病毒，因此在預測期內登革熱仍將是最大的細分市場。

在這個市場中，由於全球實驗室數量不斷增加以及臨床實驗室先進設備的可用性不斷增加，臨床實驗室可能仍然是最大的細分市場。

由於熟練的醫療保健專業人員的存在以及該地區居家醫療中擴大採用就地檢驗服務，北美在預測期內可能仍然是最大的細分市場。

常問問題

Q1.市場成長預測如何？

A1. 預計 2024 年至 2030 年，全球被忽視的熱帶疾病診斷市場將以 4.9% 的複合年成長率成長。

Q2.影響市場成長的主要促進因素有哪些？

A2. 該市場的主要驅動力是被忽視的熱帶疾病數量的增加、對快速診斷測試的需求不斷成長以及對被忽視的熱帶疾病的認知不斷提高。

Q3.市場的主要細分市場有哪些？

A3.被忽視的熱帶疾病診斷市場在醫院/診所、家庭醫療保健和臨床檢測市場的前景廣闊。

Q4.市場上主要企業有哪些？

A4.參與被忽視熱帶疾病診斷的主要企業如下。

  • F. Hoffmann-La Roche
  • Thermo Fisher Scientific
  • InBios International
  • Omega Diagnostics
  • Oscar Medicare
  • EUROIMMUN
  • Novartis
  • Grifols
  • ZeptoMetrix
  • DiaSys Diagnostic Systems

Q5.未來最大的細分市場是什麼？

A5.Lucintel 預計，由於已開發國家擴大採用就地檢驗來檢測登革熱病毒，因此在預測期內登革熱仍將是最大的部分。

Q6. 未來五年預計哪個地區將成為最大的市場？

A6. 由於熟練的醫療保健專業人員的存在以及居家醫療中擴大採用就地檢驗服務，北美在預測期內將繼續成為最大的細分市場。

Q7. 可以客製化報告嗎？

A7. 是的，Lucintel 提供 10% 的客製化服務，無需額外費用。

目錄

第1章執行摘要

第2章全球被忽視的熱帶疾病診斷市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球被忽視的熱帶疾病診斷市場趨勢（2018-2023）和預測（2024-2030）
  • 全球被忽視的熱帶疾病診斷市場：依疾病類型
    • 登革熱
    • 屈公病熱
    • 狂犬病
    • 淋巴絲蟲病
    • 布魯裡潰瘍
    • 食物中毒肺吸蟲病
    • 包蟲病
    • 麻風
    • 其他
  • 全球被忽視的熱帶疾病診斷市場：依方法分類
    • 傳統方法
    • 分子法
  • 全球被忽視的熱帶疾病診斷市場：按服務類型
    • 集中服務
    • 就地檢驗
  • 全球被忽視的熱帶疾病診斷市場：依最終用途分類
    • 醫院和診所
    • 家庭保健
    • 臨床實驗室
    • 其他

第4章 2018-2030年區域市場趨勢及預測分析

  • 全球被忽視的熱帶疾病診斷市場（按地區）
  • 北美洲被忽視的熱帶疾病診斷市場
  • 歐洲被忽視的熱帶疾病診斷市場
  • 亞太地區被忽視的熱帶疾病診斷市場
  • 其他地區被忽視的熱帶疾病診斷市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 依疾病類型
    • 依方法
    • 按服務類型
    • 按最終用途
    • 按地區
  • 全球被忽視的熱帶疾病診斷市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球被忽視的熱帶疾病診斷市場的能力
    • 全球被忽視的熱帶疾病診斷市場的合併、收購和合資企業
    • 認證和許可

第7章主要企業概況

  • F. Hoffmann-La Roche
  • Thermo Fisher Scientific
  • InBios International
  • Omega Diagnostics
  • Oscar Medicare
  • EUROIMMUN
  • Novartis
  • Grifols
  • ZeptoMetrix
  • DiaSys Diagnostic Systems
簡介目錄

Neglected Tropical Disease Diagnosis Trends and Forecast

The future of the global neglected tropical disease diagnosis market looks promising with opportunities in the hospital and clinic, home healthcare, and clinical laboratory markets. The global neglected tropical disease diagnosis market is expected to grow with a CAGR of 4.9% from 2024 to 2030. The major drivers for this market are escalating number of overlooked tropical diseases, rising demand for rapid diagnostic tests, and mounting recognition of NTDs.

A more than 150-page report is developed to help in your business decisions.

Neglected Tropical Disease Diagnosis by Segment

The study includes a forecast for the global neglected tropical disease diagnosis by disease type, method, service type, end use, and region.

Neglected Tropical Disease Diagnosis Market by Disease Type [Shipment Analysis by Value from 2018 to 2030]:

  • Dengue
  • Chikungunya
  • Rabies
  • Lymphatic Filariasis
  • Buruli Ulcer
  • Foodborne Trematodiases
  • Echinococcosis
  • Leprosy
  • Others

Neglected Tropical Disease Diagnosis Market by Method [Shipment Analysis by Value from 2018 to 2030]:

  • Conventional Method
  • Molecular Method

Neglected Tropical Disease Diagnosis Market by Service Type [Shipment Analysis by Value from 2018 to 2030]:

  • Centralized Service
  • Point-of-Care Testing

Neglected Tropical Disease Diagnosis Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital and Clinic
  • Home Healthcare
  • Clinical Laboratories
  • Others

Neglected Tropical Disease Diagnosis Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Neglected Tropical Disease Diagnosis Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies neglected tropical disease diagnosis companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the neglected tropical disease diagnosis companies profiled in this report include-

  • F. Hoffmann-La Roche
  • Thermo Fisher Scientific
  • InBios International
  • Omega Diagnostics
  • Oscar Medicare
  • EUROIMMUN
  • Novartis
  • Grifols
  • ZeptoMetrix
  • DiaSys Diagnostic Systems

Neglected Tropical Disease Diagnosis Market Insights

Lucintel forecasts that dengue will remain the largest segment over the forecast period due to increasing adoption of point-of-care testing for dengue virus detection in developed nations.

Within this market, clinical laboratory will remain the largest segment due to increased number of laboratories across world and rising availability of advanced equipment in clinical laboratories.

North America will remain the largest segment over the forecast period due to existence of skilled healthcare professionals and growing adoption of point-of-care testing services at home healthcare in the region.

Features of the Global Neglected Tropical Disease Diagnosis Market

Market Size Estimates: Neglected tropical disease diagnosis market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Neglected tropical disease diagnosis market size by various segments, such as by disease type, method, service type, end use, and region in terms of value ($B).

Regional Analysis: Neglected tropical disease diagnosis market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different disease types, methods, service types, end uses, and regions for the neglected tropical disease diagnosis market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the neglected tropical disease diagnosis market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for neglected tropical disease diagnosis market?

Answer: The global neglected tropical disease diagnosis market is expected to grow with a CAGR of 4.9% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the neglected tropical disease diagnosis market?

Answer: The major drivers for this market are escalating number of overlooked tropical diseases, rising demand for rapid diagnostic tests and mounting recognition of ntds.

Q3. What are the major segments for neglected tropical disease diagnosis market?

Answer: The future of the neglected tropical disease diagnosis market looks promising with opportunities in the hospital and clinic, home healthcare, and clinical laboratory markets.

Q4. Who are the key neglected tropical disease diagnosis market companies?

Answer: Some of the key neglected tropical disease diagnosis companies are as follows.

  • F. Hoffmann-La Roche
  • Thermo Fisher Scientific
  • InBios International
  • Omega Diagnostics
  • Oscar Medicare
  • EUROIMMUN
  • Novartis
  • Grifols
  • ZeptoMetrix
  • DiaSys Diagnostic Systems

Q5. Which neglected tropical disease diagnosis market segment will be the largest in future?

Answer: Lucintel forecasts that dengue will remain the largest segment over the forecast period due to increasing adoption of point-of-care testing for dengue virus detection in developed nations.

Q6. In neglected tropical disease diagnosis market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest segment over the forecast period due to existence of skilled healthcare professionals and growing adoption of point-of-care testing services at home healthcare in the region.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the neglected tropical disease diagnosis market by disease type (dengue, chikungunya, rabies, lymphatic filariasis, buruli ulcer, foodborne trematodiases, echinococcosis, leprosy, and others), method (conventional method and molecular method), service type (centralized service and point-of-care testing), end use (hospital and clinic, home healthcare, clinical laboratories, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Neglected Tropical Disease Diagnosis Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Neglected Tropical Disease Diagnosis Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Neglected Tropical Disease Diagnosis Market by Disease Type
    • 3.3.1: Dengue
    • 3.3.2: Chikungunya
    • 3.3.3: Rabies
    • 3.3.4: Lymphatic Filariasis
    • 3.3.5: Buruli Ulcer
    • 3.3.6: Foodborne Trematodiases
    • 3.3.7: Echinococcosis
    • 3.3.8: Leprosy
    • 3.3.9: Others
  • 3.4: Global Neglected Tropical Disease Diagnosis Market by Method
    • 3.4.1: Conventional Method
    • 3.4.2: Molecular Method
  • 3.5: Global Neglected Tropical Disease Diagnosis Market by Service Type
    • 3.5.1: Centralized Service
    • 3.5.2: Point-of-Care Testing
  • 3.6: Global Neglected Tropical Disease Diagnosis Market by End Use
    • 3.6.1: Hospital and Clinic
    • 3.6.2: Home Healthcare
    • 3.6.3: Clinical Laboratories
    • 3.6.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Neglected Tropical Disease Diagnosis Market by Region
  • 4.2: North American Neglected Tropical Disease Diagnosis Market
    • 4.2.2: North American Neglected Tropical Disease Diagnosis Market by End Use: Hospital and Clinic, Home Healthcare, Clinical Laboratories, and Others
  • 4.3: European Neglected Tropical Disease Diagnosis Market
    • 4.3.1: European Neglected Tropical Disease Diagnosis Market by Disease Type: Dengue, Chikungunya, Rabies, Lymphatic Filariasis, Buruli Ulcer, Foodborne Trematodiases, Echinococcosis, Leprosy, and Others
    • 4.3.2: European Neglected Tropical Disease Diagnosis Market by End Use: Hospital and Clinic, Home Healthcare, Clinical Laboratories, and Others
  • 4.4: APAC Neglected Tropical Disease Diagnosis Market
    • 4.4.1: APAC Neglected Tropical Disease Diagnosis Market by Disease Type: Dengue, Chikungunya, Rabies, Lymphatic Filariasis, Buruli Ulcer, Foodborne Trematodiases, Echinococcosis, Leprosy, and Others
    • 4.4.2: APAC Neglected Tropical Disease Diagnosis Market by End Use: Hospital and Clinic, Home Healthcare, Clinical Laboratories, and Others
  • 4.5: ROW Neglected Tropical Disease Diagnosis Market
    • 4.5.1: ROW Neglected Tropical Disease Diagnosis Market by Disease Type: Dengue, Chikungunya, Rabies, Lymphatic Filariasis, Buruli Ulcer, Foodborne Trematodiases, Echinococcosis, Leprosy, and Others
    • 4.5.2: ROW Neglected Tropical Disease Diagnosis Market by End Use: Hospital and Clinic, Home Healthcare, Clinical Laboratories, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Neglected Tropical Disease Diagnosis Market by Disease Type
    • 6.1.2: Growth Opportunities for the Global Neglected Tropical Disease Diagnosis Market by Method
    • 6.1.3: Growth Opportunities for the Global Neglected Tropical Disease Diagnosis Market by Service Type
    • 6.1.4: Growth Opportunities for the Global Neglected Tropical Disease Diagnosis Market by End Use
    • 6.1.5: Growth Opportunities for the Global Neglected Tropical Disease Diagnosis Market by Region
  • 6.2: Emerging Trends in the Global Neglected Tropical Disease Diagnosis Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Neglected Tropical Disease Diagnosis Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Neglected Tropical Disease Diagnosis Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: F. Hoffmann-La Roche
  • 7.2: Thermo Fisher Scientific
  • 7.3: InBios International
  • 7.4: Omega Diagnostics
  • 7.5: Oscar Medicare
  • 7.6: EUROIMMUN
  • 7.7: Novartis
  • 7.8: Grifols
  • 7.9: ZeptoMetrix
  • 7.10: DiaSys Diagnostic Systems